In a study of healthy volunteers, vildagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 RA) were the most effective agents in minimizing pasireotide-associated hyperglycemia (64). The gene discussed is GLP1R; the disease is Hyperglycemia.